HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited is set to showcase new clinical data at the 2024 ASH Annual Meeting and ESMO Asia Congress, highlighting the efficacy of its drug sovleplenib in treating chronic primary immune thrombocytopenia in China. The data reveals promising long-term results, with a significant percentage of patients showing sustained improvement in platelet counts. This development underscores HUTCHMED’s commitment to advancing cancer and immunological therapies.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
